Company: NCEL
Filing Date: 2025-03-31
Form Type: 425
Source: 0001213900-25-025889
Chunk: 102

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 425
Chunk 102
---
 of the Company.                                                                                                                                                                                                                                           |
| Im Falle von Widersprüchen zwischen dem deutschen und dem englischen Text geht der deutsche Text vor.                                                                                                                                                                                                                                                                                                                                                         |     | In case of conflicts between the German and the English text, the German text shall prevail.                                                                                                                                                                                                                                                                                                                                                                                                      |
| [Der Rest der Seite bleibt Absichtlich Leer]                                                                                                                                                                                                                                                                                                                                                                                                                  |     | [Remainder of the page intentionally left blank]                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div align='center'>67</div>

| Unterschriftenseite Zeichnungsschein /                                              
 Signatory page subscription form                                                    
 [falls juristische Person / in case of                                              
 legal entity: Name der zeichnenden Gesellschaft / Name of subscribing legal entity] 
 ______________________________                                                      
 Name:                                                                               
 Function:                                                                           
 ____________________________                                                        
 Name:                                                                               
 Function:                                                                           |

<div align='center'>68

EXHIBIT E

Company Wire Instruction

69

EXHIBIT F

NLS Pharmaceutics Ltd.

CONVERSION NOTICE</div>

Reference is made to the Securities
Purchase Agreement dated March 26, 2025, and to article 3c (Conditional Share Capital for Shareholders' Options) of the Articles
of Incorporation of NLS Pharmaceutics Ltd. (the “Company”). In accordance with and pursuant to this Conversion Notice,
the undersigned hereby elects to convert the number of Preferred Shares (the “Preferred Shares”), of the Company, indicated
below into shares of Common Shares (the “Common Shares”), of the Company, as of the date specified below.

Date of Conversion:

Number of Preferred Shares or amount Preferred Dividends
to be converted:

Tax ID Number (If applicable): ________________________________________________________________________

| Conversion Price: |

| Number of shares of Common Shares to be issued: |

The undersigned hereby agrees
that the payment of the Conversion Price will take place via offsetting the Company’s obligation to acquire the Preferred Shares
being converted from the undersigned. The undersigned agrees to offset his/her/its claims of the Company’s obligation to acquire
the Preferred Shares being converted from the undersigned against delivery of the Common Shares to be issued. Please issue the shares
of Common Shares into which the Preferred Shares are being converted in the following name and to the following address:

Issue to: _________________________________________

Address: _________________________________________

Telephone Number: ________________________________

email address: _________________________________

Purchaser: __________________________________________

By: __________________________________